What Researchers Did
Researchers conducted a systematic review and meta-analysis to evaluate the efficacy and safety of hyperbaric oxygen therapy (HBOT) for fistulizing Crohn's disease.
What They Found
Analyzing 16 studies with 164 patients, the pooled overall clinical response to HBOT was 87% and clinical remission was 59% for all fistula subtypes. Perianal and enterocutaneous fistulas showed high response rates of 89% and 84% respectively, while rectovaginal fistulas had a 29% response. The pooled number of adverse events was low, at 51.7 per 10,000 HBOT sessions.
What This Means for Canadian Patients
Hyperbaric oxygen therapy (HBOT) appears to be a safe and potentially effective treatment option for Canadian patients with fistulizing Crohn's disease. This could offer a new therapeutic avenue, particularly for perianal and enterocutaneous fistulas, though further research is needed.
Canadian Relevance
This study did not include Canadian participants or data, therefore direct Canadian relevance is not established.
Study Limitations
A significant limitation was the observed risk of bias across all included studies, highlighting the need for randomized controlled trials.